Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 8/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextromethorphan SCHEMBL29949 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL503864 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL22722074 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL12091342 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levomethorphan SCHEMBL29950 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL7380035 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20808854 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20809259 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL21095577 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL4167360 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-20190242892-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-08-08 | — | — | US | claimed |
| EP-2747754-B1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E V (DE) | 2017-04-05 | — | — | EP | claimed |
| US-9370511-B2 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2016-06-21 | — | — | US | claimed |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2015-03-26 | — | — | US | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| US-7820689-B2 | Methods and compositions for preventing or treating cardiovascular disease | WU HUA-LIN | 2010-10-26 | — | — | US | claimed |
| US-20100092478-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | claimed |
| US-20080039484-A1 | Methods and Compositions for Preventing or Treating Cardiovascular Disease | WU HUA-LIN | 2008-02-14 | — | — | US | claimed |
| US-20070203164-A1 | Methods and compositions for bactericide, bacteriostatic and anti-inflammation | BLUE BLOOD BIOTECH CORP. (TW) | 2007-08-30 | — | — | US | claimed |
| EP-0904067-B1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PFIZER HEALTH AB (SE) | 2004-12-08 | — | — | EP | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | claimed |
| US-6335030-B1 | DEXTROMETHORPHAN, 3-METHOXY-17-METHYL-9A,13A,14A-MORPHANIN, SALTS, PRODRUGS METABOLITES AND CARRIERS | PHARMACIA & UPJOHN AB (SE) | 2002-01-01 | — | — | US | claimed |
| EP-0904067-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | Pharmacia & Upjohn Aktiebolag (SE) | 1999-03-31 | — | — | EP | claimed |
| WO-1997039742-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PHARMACIA & UPJOHN AB (SE) | 1997-10-30 | — | — | WO | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124402-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| EP-4335500-A2 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | Avanir Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240067608-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240060975-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-02-22 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11845731-B2 | Methods for the synthesis of deuterated dextromethorphan | AVANIR PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-2849738-B1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO LTD (CN) | 2023-12-06 | — | — | EP | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-3825306-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4183787-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4122919-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | Avanir Pharmaceuticals, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11473123-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220196652-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-06-23 | — | — | US | disclosed |
| EP-3632916-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210348208-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3383851-B1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-3825306-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825307-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | Avanir Pharmaceuticals, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210061765-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200393462-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-12-17 | — | — | US | disclosed |
| US-10865187-B2 | Methods for the synthesis of deuterated dextromethorphan | AVANIR PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3478664-B1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10813926-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200317618-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3632916-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3603674-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN | CONCERT PHARMACEUTICALS, INC. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3357923-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10464904-B2 | Dextrorphan-derivatives with suppressed central nervous activity | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2019-11-05 | — | — | US | disclosed |
| US-10406155-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190242892-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3248978-B1 | DEUTERATED MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | disclosed |
| US-20190038618-A1 | MORPHINAN COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20180362469-A1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2018-12-20 | — | — | US | disclosed |
| US-20180344727-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180243290-A1 | MORPHINAN COMPOUNDS FOR TREATING AGITATION | CONCERT PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180246093-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180243289-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION | CONCERT PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180243291-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION | CONCERT PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| EP-3357923-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10022370-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193273-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND DEXTROMETHORPHAN | HANDA PHARMACEUTICALS, INC. (TW) | 2018-07-12 | — | — | US | disclosed |
| US-9963458-B2 | Indole and indoline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9891219-B2 | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3093290-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9868976-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2365808-B1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-3248978-A1 | DEUTERATED MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2805950-B1 | Deuterated morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170281616-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9744165-B2 | Method for treating hypertension | TSH BIOPHARM CORPORATION LTD. (TW) | 2017-08-29 | — | — | US | disclosed |
| US-9655895-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2747754-B1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E V (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-20170037449-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2017020014-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR USE IN TREATING AGITATION | CONCERT PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017020002-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR USE IN TREATING AGITATION | CONCERT PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-3093290-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-3090760-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160287579-A1 | MORPHINAN COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9456985-B2 | Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160235741-A1 | METHOD FOR TREATING HYPERTENSION | TSH BIOPHARM CORP LTD (TW) | 2016-08-18 | — | — | US | disclosed |
| US-9370511-B2 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20160143902-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9340512-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9314440-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2397158-B1 | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2792662-B1 | Morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2418211-B1 | Deuterated morphinane compounds | CONCERT PHARMACEUTICALS INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160051475-A1 | Sustained Release Composition Comprising an Amine as Active Agent and a Salt of a Cyclic Organic Acid | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-9266837-B2 | Morphinan compounds | Concert Phamaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | TADESSE DAWIT (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150336899-A1 | MORPHINAN COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150315201-A1 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-05 | — | — | US | disclosed |
| US-20150238485-A1 | OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS | SHIONOGI & CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238423-A1 | Sustained-Released Product Comprising a Combination of a Non-Opioid Amine and a Non-Steroidal, Anti-Inflammatory Drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-9072711-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2357183-B1 | Morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015078382-A1 | ENDO-(14S)-3-METHOXY-17-METHYLMORPHINAN PICRATE AND PREPARATION METHOD AND USE THEREOF | 浙江普洛康裕制药有限公司 | 2015-06-04 | — | — | WO | disclosed |
| US-9023390-B2 | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150104813-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | disclosed |
| US-20150073009-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| EP-2522668-B1 | Morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8916582-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2805950-A1 | Deuterated morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2634187-B1 | Deuterated morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140329846-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140315940-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2792662-A1 | Morphinan compounds | Concert Pharmaceuticals Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2522667-B1 | Morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2747754-A1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | Heinrich-Heine-Universität Düsseldorf (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-8748450-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8710072-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140113925-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310415-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8541436-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130237559-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | UPSHER-SMITH LABORATORIES, INC. | 2013-09-12 | — | — | US | disclosed |
| EP-2634187-A1 | Deuterated morphinane compounds | Concert Pharmaceuticals Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225627-A1 | DEXTROMETHORPHAN ANTITUSSIVE COMPOSITIONS | TRINITY LABORATORIES, INC. (TX) | 2013-08-29 | — | — | US | disclosed |
| EP-2588085-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | Upsher-Smith Laboratories, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2013029762-A1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053411-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION | TSH BIOPHARM CORPORATION LTD. (TW) | 2013-02-28 | — | — | US | disclosed |
| US-20130012483-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEURODEGENERATIVE OR NEUROVASCULAR DISEASES | CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS (FR) | 2013-01-10 | — | — | US | disclosed |
| EP-2334678-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2345653-B1 | Morphinan compounds | CONCERT PHARMACEUTICALS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2522668-A1 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522667-A1 | Morphinan compounds | Concert Pharmaceuticals Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120252833-A1 | SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STERIODAL ANTI-INFLAMMATORY DRUG | UPSHER-SMITH LABORATORIES, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8188110-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120083487-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120053169-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS INC. | 2012-03-01 | — | — | US | disclosed |
| EP-2152709-B1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2418211-A1 | Deuterated morphinane compounds | Concert Pharmaceuticals Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120029007-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. | 2012-02-02 | — | — | US | disclosed |
| WO-2012003231-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | UPSHER-SMITH LABORATORIES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| EP-2397159-A2 | Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397158-A2 | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110306627-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110257214-A1 | MORPHINAN COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110230514-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2365808-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | Concert Pharmaceuticals Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364151-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | Concert Pharmaceuticals Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2357183-A1 | Morphinan compounds | Concert Pharmaceuticals Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2345653-A1 | Morphinan compounds | Concert Pharmaceuticals Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7973049-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2334678-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7939567-B2 | Dextromethorphan-based method for treating acne | BLUE BLOOD BIOTECH CORP. (TW) | 2011-05-10 | — | — | US | disclosed |
| US-7820689-B2 | Methods and compositions for preventing or treating cardiovascular disease | WU HUA-LIN | 2010-10-26 | — | — | US | disclosed |
| WO-2010062692-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062690-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100092478-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| WO-2010033801-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-2152709-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080280936-A1 | Morphinan Compounds | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008137474-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080108643-A1 | METHOD FOR TREATING AUTISM | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-08 | — | — | US | disclosed |
| US-20080039527-A1 | Calixarenes as Inhibitors of Protein Kinase B | IMPERIAL COLLEGE INNOVATIONS LTD. | 2008-02-14 | — | — | US | disclosed |
| US-20080039484-A1 | Methods and Compositions for Preventing or Treating Cardiovascular Disease | WU HUA-LIN | 2008-02-14 | — | — | US | disclosed |
| US-20070203164-A1 | Methods and compositions for bactericide, bacteriostatic and anti-inflammation | BLUE BLOOD BIOTECH CORP. (TW) | 2007-08-30 | — | — | US | disclosed |
| EP-0904067-B1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PFIZER HEALTH AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-0904067-B1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PFIZER HEALTH AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004091589-A1 | TRANSDERMALLY ADMINISTERABLE TRANQUILIZING AND SEDATING AGENT | MUTZBAUER TILL S (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6335030-B1 | DEXTROMETHORPHAN, 3-METHOXY-17-METHYL-9A,13A,14A-MORPHANIN, SALTS, PRODRUGS METABOLITES AND CARRIERS | PHARMACIA & UPJOHN AB (SE) | 2002-01-01 | — | — | US | disclosed |
| EP-0904067-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | Pharmacia & Upjohn Aktiebolag (SE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0904067-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | Pharmacia & Upjohn Aktiebolag (SE) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997039742-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PHARMACIA & UPJOHN AB (SE) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997039742-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PHARMACIA & UPJOHN AB (SE) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997039742-A1 | TRANSDERMALLY ADMINISTERED DEXTROMETHORPHAN AS ANTITUSSIVE AGENT | PHARMACIA & UPJOHN AB (SE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | GRIN2A 125/4885SIGMAR1 26/4885GRIN1 190/4885 |
| US-20150238485-A1 | OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS | OPRL1, OGFRL1, OPRD1 | GRIN2A 487/4885SIGMAR1 16/4885GRIN1 136/4885 |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | GRIN2A 3761/4885SIGMAR1 3110/4885GRIN1 3528/4885 |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | GRIN2A 125/4885SIGMAR1 26/4885GRIN1 190/4885 |
| US-20120053169-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, OPRL1, DBH | GRIN2A 129/4885SIGMAR1 24/4885GRIN1 193/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | GRIN2A 4045/4885SIGMAR1 2776/4885GRIN1 3922/4885 |
| US-11845731-B2 | Methods for the synthesis of deuterated dextromethorphan | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20210348208-A1 | Morphinan Compounds | GRIN1, GRIN2A, GRIN3A | GRIN2A 2/4885SIGMAR1 199/4885GRIN1 1/4885 |
| US-20240067608-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20150073009-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20140329846-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20200317618-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20150336899-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20080039527-A1 | Calixarenes as Inhibitors of Protein Kinase B | CAMK2B, PNCK, CAMK1 | GRIN2A 2106/4885SIGMAR1 2435/4885GRIN1 1894/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | GRIN2A 3761/4885SIGMAR1 3110/4885GRIN1 3528/4885 |
| US-20110230514-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20110257214-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | GRIN2A 3761/4885SIGMAR1 3110/4885GRIN1 3528/4885 |
| US-10464904-B2 | Dextrorphan-derivatives with suppressed central nervous activity | BDNF, NR1D1, NR1D2 | GRIN2A 9/4885SIGMAR1 726/4885GRIN1 13/4885 |
| US-20080039484-A1 | Methods and Compositions for Preventing or Treating Cardiovascular Disease | PCSK9, HMGCR, TNNI3 | GRIN2A 4518/4885SIGMAR1 4827/4885GRIN1 4603/4885 |
| US-20180344727-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | GRIN2A 125/4885SIGMAR1 26/4885GRIN1 190/4885 |
| US-11473123-B2 | Morphinan compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20180362469-A1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | BDNF, NR1D1, NR1D2 | GRIN2A 9/4885SIGMAR1 726/4885GRIN1 13/4885 |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | INSR, GPR119, OPRM1 | GRIN2A 30/4885SIGMAR1 49/4885GRIN1 5/4885 |
| US-20160051475-A1 | Sustained Release Composition Comprising an Amine as Active Agent and a Salt of a Cyclic Organic Acid | OPRK1, OPRM1, OPRL1 | GRIN2A 607/4885SIGMAR1 6/4885GRIN1 512/4885 |
| US-20120083487-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, SLC6A2, DBH | GRIN2A 94/4885SIGMAR1 33/4885GRIN1 119/4885 |
| US-20180243289-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION | DRD2, DRD1, NLN | GRIN2A 74/4885SIGMAR1 419/4885GRIN1 128/4885 |
| US-10865187-B2 | Methods for the synthesis of deuterated dextromethorphan | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-10406155-B2 | Morphinan compounds | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20130237559-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | OPRK1, OPRM1, OPRL1 | GRIN2A 607/4885SIGMAR1 6/4885GRIN1 512/4885 |
| US-20080108643-A1 | METHOD FOR TREATING AUTISM | GRIN2A, PNMT, GRIN3A | GRIN2A 1/4885SIGMAR1 318/4885GRIN1 37/4885 |
| US-20120252833-A1 | SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STERIODAL ANTI-INFLAMMATORY DRUG | SIGMAR1, OPRM1, OPRK1 | GRIN2A 460/4885SIGMAR1 1/4885GRIN1 331/4885 |
| US-20190038618-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | GRIN2A 32/4885SIGMAR1 13/4885GRIN1 73/4885 |
| US-20180243291-A1 | DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION | DRD2, DRD1, NLN | GRIN2A 74/4885SIGMAR1 419/4885GRIN1 128/4885 |
| US-20180243290-A1 | MORPHINAN COMPOUNDS FOR TREATING AGITATION | NLN, ATXN10, HTR5A | GRIN2A 36/4885SIGMAR1 531/4885GRIN1 88/4885 |
| US-20160287579-A1 | MORPHINAN COMPOUNDS | GRIN1, GRIN2A, GRIN2B | GRIN2A 2/4885SIGMAR1 337/4885GRIN1 1/4885 |
| US-20210061765-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20240124402-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | GRIN2A 3761/4885SIGMAR1 3110/4885GRIN1 3528/4885 |
| US-20080280936-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20170037449-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-10813926-B2 | Morphinan compounds | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20170281616-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-10022370-B2 | Morphinan compounds | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
| US-20070203164-A1 | Methods and compositions for bactericide, bacteriostatic and anti-inflammation | IL6, TNF, OPRD1 | GRIN2A 3087/4885SIGMAR1 26/4885GRIN1 1903/4885 |
| US-20140113925-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20110306627-A1 | Morphinan Compounds | OPRM1, SIGMAR1, OPRK1 | GRIN2A 9/4885SIGMAR1 2/4885GRIN1 6/4885 |
| US-20160143902-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, SLC6A2 | GRIN2A 94/4885SIGMAR1 31/4885GRIN1 117/4885 |
| US-20140315940-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | GRIN2A 8/4885SIGMAR1 5/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.